SEC Form 4 · accession 0001209191-16-152233

FIVE PRIME THERAPEUTICS INC · FPRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Strategy Officer

Period of report

Nov 23, 2016

Accepted (ET)

Nov 28, 2016 · 7:40 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001175505

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Nov 23, 2016	M	13,465	$6.89	A	94,731	D
Common Stock^F2	Nov 23, 2016	S	13,465	$60.23	D	81,266	D
Common Stock	Nov 25, 2016	M	10,925	$6.89	A	92,191	D
Common Stock	Nov 25, 2016	M	10,264	$5.54	A	102,455	D
Common Stock^F3	Nov 25, 2016	S	21,189	$60.48	D	81,266	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F4	$6.89	Nov 23, 2016	M	13,465	D	—	Jan 27, 2021	Common Stock	13,465	10,925	D
Employee Stock Option (right to buy)^F4	$6.89	Nov 25, 2016	M	10,925	D	—	Jan 27, 2021	Common Stock	10,925	0	D
Employee Stock Option (right to buy)^F4	$5.54	Nov 25, 2016	M	10,264	D	—	Jul 15, 2022	Common Stock	10,264	14,488	D

F1The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on October 27, 2015.
F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.40, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.98, inclusive.
F4This option is fully vested and immediately exercisable.